Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Insight Molecular Diagnostics Inc. (IMDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-incorporated public company listed on Nasdaq, Insight Molecular Diagnostics files current and periodic reports that describe its financial condition, governance decisions, and key developments in its precision diagnostics business.
Through forms such as 8-K, investors can review announcements related to executive compensation changes, stock option grants under the company’s equity incentive plan, amendments to employment agreements, and other material events. Earnings-related 8-K filings furnish press releases that summarize quarterly financial results and business updates, including progress on the GraftAssure dd-cfDNA transplant testing platform.
In addition to current reports, users can locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy materials that address governance matters and executive compensation. These filings provide context on how Insight Molecular Diagnostics manages its transplant-focused diagnostics programs, quality and regulatory activities, and broader corporate strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major topics without reading every page. Real-time updates from EDGAR ensure that new IMDX filings, including any future registration statements or insider transaction reports on Form 4, are added as they become available. This page is a central resource for analyzing the regulatory record of Insight Molecular Diagnostics and its dd-cfDNA-based diagnostics business.
Insight Molecular Diagnostics Inc. entered into a material Specimen Collection Agreement with Quest Diagnostics Incorporated on February 20, 2026. Quest Diagnostics will provide specimen collection-related services for samples on which Insight will perform its GraftAssureCore™ blood test, which measures donor-derived cell free DNA using a PCR-based platform.
The parties also agreed that, for a specified period, they will use commercially reasonable efforts to negotiate in good faith additional rights related to the GraftAssure technology. Fees will be paid to Quest Diagnostics for the services under this agreement.
Insight Molecular Diagnostics Inc. saw a major shareholder deepen its stake through a new stock purchase agreement. Broadwood Partners, Broadwood Capital and Neal C. Bradsher reported beneficial ownership of 12,081,932 to 12,082,089 common shares, equal to 37.4% of the company’s stock based on 32,297,028 shares outstanding.
On February 10, 2026, Broadwood Partners agreed to acquire an additional 521,739 shares from the company in a registered direct offering at $5.75 per share, for a combined purchase price of $2,999,999. The investors state the shares are held for investment and may engage with management and other shareholders on ways to enhance long-term value.
Insight Molecular Diagnostics Inc. reported that Broadwood Partners, L.P., a 10% owner, bought additional shares of its common stock. On February 10, 2026, Broadwood Partners agreed to acquire 521,739 common shares from the company in a registered direct offering for $2,999,999, or $5.75 per share, bringing its reported beneficial ownership to 11,931,839 shares.
The filing notes that these shares are directly owned by Broadwood Partners and may be deemed beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher, who each disclaim beneficial ownership beyond their economic interest. The group also reports warrants currently exercisable for 150,093 common shares.
Insight Molecular Diagnostics Inc. entered into securities purchase agreements with institutional investors for a registered direct offering of 3,482,498 common shares and pre-funded warrants to purchase up to 1,043,478 shares at $5.75 per share (or $5.7499 per pre-funded warrant).
The transaction is expected to generate aggregate gross proceeds of approximately $26.0 million and net proceeds of about $24.5 million after placement fees and expenses. The company plans to use the funds for general corporate purposes, focusing on transplantation R&D and expanding its GraftAssure product line, including heart transplant rejection testing.
The pre-funded warrants carry a $0.0001 exercise price and are exercisable until fully exercised, subject to a beneficial ownership cap of 4.99% or, at the holder’s election, 9.99% of outstanding common stock, adjustable with at least 61 days’ prior notice.
Insight Molecular Diagnostics Inc. is conducting a primary offering of 3,482,498 shares of common stock and pre-funded warrants to purchase up to 1,043,478 additional shares of common stock. The shares are priced at $5.75 each and the pre-funded warrants at $5.7499, for gross proceeds of $26,024,257.65. Net proceeds are expected to be approximately $24.5 million after placement fees and expenses. The company plans to use the cash mainly for general corporate purposes and research and development in transplantation, including expanding its GraftAssure transplant rejection testing from kidneys into other organs, most immediately heart. Assuming full exercise of the pre-funded warrants, shares outstanding would be 33,151,381, and the transaction increases net tangible book value from $(0.83) to $0.02 per share, implying dilution of $5.73 per share to new investors.
Insight Molecular Diagnostics Inc. filed a current report to notify investors that it may use a new slide presentation in meetings with investors or analysts. The presentation is attached as Exhibit 99.1 and may be used from time to time to discuss the company and its business.
The company states that this material is being furnished under a disclosure item for Regulation FD and is not considered filed for purposes of liability under the Exchange Act. The presentation will only be incorporated into other SEC filings if explicitly referenced there.
Insight Molecular Diagnostics (IMDX) filed a Form 4/A reporting that its Chief Financial Officer, Andrea James, had 50,000 shares of common stock issued at $0 upon vesting of performance-based RSUs on 10/31/2025. To cover taxes, 12,175 shares were withheld at $6.01; no shares were sold. Following these transactions, she directly beneficially owned 189,056 shares.
The RSUs vested after the company’s public float reached at least $75 million, satisfying a “Baby Shelf” condition that ended Form S-3 “baby shelf” limitations. This amendment corrects the original report to include the tax withholding.
Insight Molecular Diagnostics (IMDX) filed its Q3 2025 10‑Q, reporting net revenue of $260K versus $115K a year ago and a net loss of $10.9M versus $13.5M. Gross profit was $139K as operating expenses reached $11.2M, including R&D of $3.9M and sales and marketing of $1.4M.
For the nine months, revenue was $2.916M versus $395K last year, with a net loss of $27.3M. Operating cash use was $16.6M. The balance sheet showed cash and cash equivalents of $18.7M, total assets of $43.9M, total liabilities of $53.1M, and a shareholders’ deficit of $9.2M.
Management evaluated going concern and concluded it will have sufficient cash for at least the next 12 months, aided by cost controls and the February 2025 offering that raised $29.1M gross (net proceeds ~$28.7M). Commercial progress included Medicare coverage and a $2,753 per‑result reimbursement for GraftAssureCore and initial RUO kit sales under the Bio‑Rad partnership. Common shares outstanding were 28,664,437 as of November 3, 2025.
Insight Molecular Diagnostics Inc. (IMDX) furnished an 8‑K to announce that it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The Company noted that the information provided under Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor automatically incorporated into other filings except as specifically referenced. IMDX’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMDX.
Insight Molecular Diagnostics (IMDX) reported an insider equity change: the CFO acquired 50,000 shares of Common Stock on 10/31/2025 via the vesting and settlement of performance-based RSUs at a stated price of $0. The vesting was triggered when the company’s public float reached at least $75 million, satisfying the “Baby Shelf” performance condition tied to Form S-3 eligibility.
Following the transaction, the reporting person beneficially owned 201,231 Common shares directly. The RSUs were granted under the company’s 2018 Equity Incentive Plan, with each RSU representing the right to receive one share upon settlement. The filing notes that this milestone resulted in the vesting of 50% of the RSUs granted to the reporting person, subject to continued service.